Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study
- DOI
- 10.3389/fimmu.2026.1844354
- Published
- 2026-06-15
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1844354,
title = {Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study},
author = {Marta Codirenzi and Federica Davanzo and Luca Iorio and Eleonora Fiorin and Gabriella Guarnieri and Fulvia Chieco Bianchi and Alessia Achille and Maria Rita Marchi and Andrea Vianello and Andrea Doria and Roberta Ramonda and Roberto Padoan},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1844354},
url = {https://doi.org/10.3389/fimmu.2026.1844354}
}RIS
TY - JOUR TI - Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study AU - Marta Codirenzi AU - Federica Davanzo AU - Luca Iorio AU - Eleonora Fiorin AU - Gabriella Guarnieri AU - Fulvia Chieco Bianchi AU - Alessia Achille AU - Maria Rita Marchi AU - Andrea Vianello AU - Andrea Doria AU - Roberta Ramonda AU - Roberto Padoan PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1844354 UR - https://doi.org/10.3389/fimmu.2026.1844354 ER -
APA
Codirenzi, M., Davanzo, F., Iorio, L., Fiorin, E., Guarnieri, G., Bianchi, F. C., Achille, A., Marchi, M. R., Vianello, A., Doria, A., Ramonda, R., & Padoan, R. (2026). Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1844354
Source records
- crossref · retrieved 2026-09-27T04:03:59.548Z